33 results
8-K
EX-99.1
SPRY
ARS Pharmaceuticals Inc
7 Mar 24
Results of Operations and Financial Condition
12:56pm
use it? Ø Consistent and reproducible PK/PD Ø No risk of injury and Ø Minimal side effects profiles (no to minimal outliers) and minimal side effects … %) Ø Rapid efficacy profile in OFC anaphylaxis Ø Palatable – no meaningful (100% response rate in first 15 min), as Ø No risk of injury (no needle
8-K
EX-10.4
0520a0qy bw6
8 Nov 22
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
4:51pm
8-K
EX-10.3
s0vu34 beiwgl97pt
8 Nov 22
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
4:51pm
8-K
EX-10.5
rh5xjrudurc pyobgzf
8 Nov 22
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
4:51pm
DEFM14A
oet 8ujvtyikdf4
6 Oct 22
Proxy related to merger
4:16pm
PRER14A
eqyv0fd lt05ie97kgvc
16 Sep 22
Preliminary revised proxy
4:56pm
PREM14A
h9ql4keym4vfo nq2ktc
11 Aug 22
Preliminary proxy related to merger
5:22pm